Ancor-2.5 Tablet: Each tablet contains Bisoprolol Fumarate USP 2.5 mg.
Ancor-5 Tablet: Each tablet contains Bisoprolol Fumarate USP 5 mg.
Ancor-10 Tablet: Each tablet contains Bisoprolol Fumarate USP 10 mg.
Bisoprolol Fumarate is the most selective beta-1 blocker. It has highest level of affinity for the beta-1 receptor than any other beta-blocker available up to now. It selectively blocks beta-1 adrenergic receptor in the heart and vascular smooth muscle and reduces heart rate and cardiac output resulting in decrease of arterial hypertension. Lipid metabolism can be adversely affected by beta-1 blockers, in patients with non-selective beta-blocker, but Bisoprolol does not cause any change in the cholesterol fraction including the cardioprotective HDL-cholesterol in long-term therapy.
Hypertension, angina and adjunct in stable moderate to severe heart failure.
Bisoprolol should not be combined with other beta-blocking agents.
In patients with cardiogenic shock, overt heart failure, second or third degree A-V block, right ventricular failure secondary to pulmonary hypertension and sinus bradycardia.
Gastro-intestinal disturbances, bradycardia, hypotension, peripheral vasoconstriction, headache, fatigue, sleep disturbances, dizziness, vertigo, sexual dysfunction; thrombocytopenia; visual disturbances, alopecia may be occurred.
Use in pregnancy: The safety of bisoprolol during pregnancy has not been established.
Use in lactation: No data is available for lactation.
Use in children: Safety and effectiveness in children have not been established.
Monitoring of renal, hepatic, and hematopoietic function should be performed at regular intervals during long-term treatment with bisoprolol.